PDCD1 and glioblastoma: They found that when compared to no treatment group mice, the combination therapy significantly affected survival (P ═ 0.03); moreover, there was a clinical trial involving the combination of anti-LAG-3 and anti-PD-1 in the treatment of glioblastoma (NCT02658981) [69].